The estimated Net Worth of Kurt Graves is at least $606 mil dollars as of 16 April 2019. Mr. Graves owns over 4,800 units of Seres Therapeutics Inc stock worth over $5,775 and over the last 17 years he sold MCRB stock worth over $522,374. In addition, he makes $78,152 as Independent Director at Seres Therapeutics Inc.
Kurt has made over 15 trades of the Seres Therapeutics Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 4,800 units of MCRB stock worth $107,136 on 16 April 2019.
The largest trade he's ever made was exercising 25,000 units of Seres Therapeutics Inc stock on 6 July 2015 worth over $183,500. On average, Kurt trades about 1,681 units every 72 days since 2007. As of 16 April 2019 he still owns at least 5,500 units of Seres Therapeutics Inc stock.
You can see the complete history of Mr. Graves stock trades at the bottom of the page.
Kurt C. Graves serves as Independent Director of the Company. Mr. Graves has been the Chairman, President and Chief Executive Officer of Intarcia Therapeutics, Inc. (“Intarcia”), a biotechnology company, since April 2012 and Executive Chairman from August 2010 to April 2012. Mr. Graves previously served as Executive Chairman of Biolex Therapeutics, a biopharmaceutical company, from November 2010 to March 2012, and as Executive Chairman of Intarcia from August 2010 to April 2012. Previously, he served as Executive Vice President, Chief Commercial Officer and Head of Strategic Development at Vertex Pharmaceuticals Inc. (“Vertex”), from July 2007 to October 2009. Prior to joining Vertex, Mr. Graves held various leadership positions at Novartis Pharmaceuticals Corporation (“Novartis Corp.”), from 1999 to June 2007, including the Chief Marketing Officer for the pharmaceuticals division of Novartis Corp. from September 2003 to June 2007. He also has served on the boards directors of Intarcia Therapeutics, Inc. since 2010, Radius Health, Inc. since 2011, and Achillion Pharmaceuticals, Inc. since 2012. Mr. Graves received a B.S. in Biology from Hillsdale College.
As the Independent Director of Seres Therapeutics Inc, the total compensation of Kurt Graves at Seres Therapeutics Inc is $78,152. There are 7 executives at Seres Therapeutics Inc getting paid more, with Eric Shaff having the highest compensation of $2,032,550.
Kurt Graves is 52, he's been the Independent Director of Seres Therapeutics Inc since 2015. There are 12 older and 8 younger executives at Seres Therapeutics Inc. The oldest executive at Seres Therapeutics Inc is Dennis Ausiello, 74, who is the Independent Director.
Kurt's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140.
Over the last 9 years, insiders at Seres Therapeutics Inc have traded over $37,132,594 worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth $47,525,463 . The most active insiders traders include Noubar Afeyan, Health Ltp Fund General Par..., eHealth Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $251,393. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth $2,789.
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
Seres Therapeutics Inc executives and other stock owners filed with the SEC include: